Abstract 338P
Background
Indigenous Australian above age 55 is classed as geriatrics age group. No study has been done in geriatrics indigenous women with breast cancer of WA. The study comprehensively analyzes the cohort with respect to the co-morbidities burden, remoteness, social isolation and toxicity burden in two groups in Western Australia.Aim is to analyze the retrospective data and validate predictive tools in this population.
Methods
Data collected retrospectively of Breast Cancer (BrCa) women from the WA cancer Registry between 2001 and 2010. A cohort of patients was selected comprising age- and remoteness (defined by ARIA) matched patients in a 1:1 ratio. A total of 102 Indigenous Geriatric patients were identified aged 55 years and above, matched to Non-Indigenous geriatric patients. For in-depth comparison, two main tools were employed; CARG prediction tool (CARG score) to analyze possible severity of toxicity and comorbidity burden using Charlson Co-morbidity Index (CCI) in the groups and association to social isolation and mortality; BrCa specific and all-cause mortality. The Mann Whitney U test was employed based on observation of data type,among others.
Results
Data from 65 Indigenous and Non-Indigenous patients were available. The CARG score of all Indigenous group was mean of 8.86 +/- 4.16 SD and Non-Indigenous was mean of 6.97 +/- 3.13 SD (p= 0.01). The CCI points was mean 7.45 +/- 3.01 SD in Indigenous group versus mean 5.47 +/- 1.71 SD (p=0.0005). In Indigenous group, 80 and above CARG average score is 15.16 and toxicity is 72.16 % versus average of 9.70 and 67.76 % in Non Indigenous group (p<0.0001). The BrCa mortality in Indigenous group remains higher with CARG toxicity of 66 % and CCI points average of 8.66 versus 55.25 % and average of 7.25 respectively (p=0.04). Remoteness had Indigenous mortality of 40.8 % versus 11.7% in Non-Indigenous (p=0.14). Social isolation reported more in Indigenous group then Non-Indigenous group (22 months vs. 53 months,p=0.03).
Conclusions
Indigenous geriatric population has more treatment toxicity and co-morbidity burden impacting survival between two groups. A better policy and prediction model directed towards Indigenous Geriatric population is needed to improve the disparity between groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Azim Khan.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.